Fig. 1.
Mean pre- and post-treatment TLC and IL6 values in the LA and placebo groups
| Pre-treatment | Post-treatment | ||||
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | MD | % of change | p-value | |
| TLC (cells/uL) | |||||
| LA Group A | 1516 ± 143.95 | 1834.43 ± 127.56 | −318.43 | 21 | 0.001 |
| Placebo Group | 1554.45 ± 136.57 | 1582.27 ± 142.78 | −27.82 | 1.79 | 0.02 |
| MD | −38.45 | 252.16 | |||
| p = 0.24 | p = 0.001 | ||||
| IL6 (pg/ml) | |||||
| LA Group A | 64.51 ± 20.24 | 50.05 ± 18.25 | 14.46 | 22.42 | 0.001 |
| Placebo Group | 66.11 ± 23.11 | 64.75 ± 22.98 | 1.36 | 2.06 | 0.12 |
| MD | −1.6 | −14.7 | |||
| p = 0.75 | p = 0.003 | ||||
Median pre and post-treatment dyspnea and Chalder fatigue scale values in the LA and placebo groups
| Pre-treatment | Post-treatment | |||
|---|---|---|---|---|
| Median (IQR) | Median (IQR) | Z-value | p-value | |
| Dyspnea scale | ||||
| LA Group | 2 (2–1) | 1 (1–0) | −4.54 | 0.001 |
| Placebo Group | 2 (2–1) | 1 (2–1) | −3.3 | 0.001 |
| U-value | 640 | 451 | ||
| p = 0.59 | p = 0.007 | |||
| Chalder fatigue scale | ||||
| Group A | 5 (6–4) | 3 (4–3) | −5.31 | 0.001 |
| Group B | 5 (6–4) | 5 (5–4) | −1.63 | 0.1 |
| U-value | 581 | 123.5 | ||
| p = 0.24 | p = 0.001 | |||
Comparison of subject characteristics between LA and Placebo groups
| LA Group | Placebo Group | MD | t-value | p-value | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | ||||
| Age (years) | 36.13 ± 2.78 | 35.86 ± 3.09 | 0.27 | 0.39 | 0.69 |
| BMI (kg/m2) | 32.36 ± 1.18 | 32.14 ± 1.09 | 0.12 | 0.862 | 0.391 |
| Weight (kg) | 90.19 ± 6.82 | 90.11 ± 6.84 | 0.08 | 0.053 | 0.958 |
| Height (m) | 1.67 ± 0.07 | 1.67 ± 0.07 | 0.00 | −0.295 | 0.769 |